Exploration and challenges of neoadjuvant therapy in the management of resectable hepatocellular carcinoma
10.3969/j.issn.1006-5725.2025.23.022
- VernacularTitle:新辅助治疗在可切除性肝细胞癌管理中的探索和挑战
- Author:
Xin LIU
1
;
Yutao HE
1
;
Fangming TIAN
1
;
Haocheng TANG
1
;
Zhitian SHI
1
;
Lin WANG
1
Author Information
1. 昆明医科大学第二附属医院肝胆胰外科二病区(云南 昆明 650033)
- Publication Type:Journal Article
- Keywords:
hepatocellular carcinoma;
neoadjuvant therapy;
transcatheter arterial chemoembolization;
hepatic arterial infusion chemotherapy;
molecular targeted therapy;
immunotherapy
- From:
The Journal of Practical Medicine
2025;41(23):3780-3785
- CountryChina
- Language:Chinese
-
Abstract:
Neoadjuvant therapy for hepatocellular carcinoma is the frontier and hot topic in the current field of liver cancer research.The fundamental purpose is to reduce the risk of postoperative recurrence through standardized preoperative treatment methods.From the attempts of Transcatheter Arterial Chemoembolization monotherapy for neoadjuvant therapy for hepatocellular carcinoma to systematic treatment represented by"targeted combined with immunotherapy",the latter has become the most promising neoadjuvant strategy due to its high objective response rate and potential to induce pathological complete remission.However,the field still faces challenges such as lack of evidence of overall survival benefit in Phase Ⅲ randomized controlled trials,treatment-related adverse reactions that may lead to delay in surgery,optimal population screening,and timing of surgery.This article aims to briefly discuss the current research status of the application of neoadjuvant therapy in resectable hepatocellular carcinoma,explore relevant diagnosis and treatment concepts,and further understand neoadjuvant therapy.
